Roche Holding AG plans to initiate a pair of new pivotal phase III studies testing the beta-amyloid-targeting monoclonal antibody gantenerumab in patients with prodromal to mild Alzheimer's disease (AD) in hopes that a higher dose of the drug might yield benefits that lower doses did not.